Angion Biomedica Corporation

Osi Pharmaceuticals, Inc.

Anigion Biomedica Corp.

Bijoy Panicker

Andrew Philip Crew

Lambertus J W M Oehlen

Mark Joseph Mulvihill

Ayako Honda

Lee Daniel Arnold

Heather Renee Coate

Douglas S Werner

Dong Sung Lim

An-Hu Li

Rama K Mishra

Kristen Michelle Mulvihill

Dawoon Jung

Jing Wang

Hanqing Dong

Xin Chen

Kam W Siu

Meizhong Jin

James David Beard

Han-Qing Dong

Brian Volk

Paula A R Tavares

Apoorba Bharadwaj

Quinghua Weng

Qinghua Weng

James G Tarrant

Radoslaw Laufer

Arno G Steinig

Yingchuan Sun

Kenneth W Foreman

Tao Zhang

Anthony Innocenzo Nigro

Cara Cesario

Michael J Wyle

Xiaokang Zhu

Jason Bloxham

Amo G Steinig

Lifu Ma

David E Smith

Dan Maarten Berger

Neil Anthony Pegg

Shazia Sadiq

Colin Peter Sambrook Smith

Andrew Kleinberg

John Kitchin

Graham Wynne

Robin Wilkes

Oscar Barba

Keith Hornberger

Ramesh C Gupta

Kathryn M Stolz

William Gattrell

Saleh Ahmed

Graham Dawson

Imaad Saba

Don Smyth

Matthew Cox

Prakash Narayan

Weizhong Cai

Rajaram Sangem

Qinghua (‘Felix’) Weng

Kenneth (‘Ken’) Foreman

Paula Tavares

Lawrence Tardibono, Jr

Lambertus JWM Oehlen

Andrew-Philip Crew

Lee D Arnoldd

Paula AR Tavares

The present invention provides compounds having the general structural formula (I) and pharmaceutically acceptable derivatives thereof, as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of any of a number of conditions or diseases involving abnormal or excessive fibrosis.

Antifibrotic compounds and uses thereof

The present invention provides compounds having the general structural formula (I) (I) and pharmaceutically acceptable derivatives thereof, as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of any of a number of conditions or diseases involving fibrosis and proliferation, and where anti-fibrotic or anti-proliferative activity is beneficial. 

Cytochrome P450 inhibitors and uses thereof

The present invention provides compounds having the general structural formula (I) and pharmaceutically acceptable derivatives thereof, as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of any of a number of conditions or diseases involving elevated levels of aldosterone or abnormal or excessive fibrosis, such as kidney disease and hypertension.

Methods and agents for treating disease

The present invention provides compounds having the general structural formula (I) and pharmaceutically acceptable derivatives thereof, as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of any of a number of conditions or diseases involving fibrosis and proliferation, and where anti-fibrotic or anti-proliferative activity is beneficial.

The present invention provides compounds having the general structural formula (I) [formula should be inserted here] and pharmaceutically acceptable derivatives thereof, as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of any of a number of conditions or diseases involving elevated levels of aldosterone or abnormal or excessive fibrosis, such as kidney disease and hypertension. 

The present invention provides compounds having the general structural formula (I), and pharmaceutically acceptable derivatives thereof, as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of any of a number of conditions or diseases involving abnormal or excessive fibrosis. 

Compounds represented by Formula (I) or a pharmaceutically acceptable salt thereof, are inhibitors of mTOR and useful in the treatment of cancer.

Fused bicyclic mTOR inhibitors

The present invention provides compositions and formulations of compounds having formula (I) and pharmaceutically acceptable derivatives thereof, wherein p, R, Rand B are as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of any of a number of injuries, conditions or diseases in which HGF/SF or the activities thereof, or agonists or antagonists thereof have a therapeutically useful role. In addition, methods are provided for treating such diseases or diseases starting at a time after the onset of the injury, condition or disease. 

Methods and compositions of small molecule modulators of hepatocyte growth factor (scatter factor) activity

6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors

Growing community of inventors

Holbrook, NY, United States of America

Bijoy Panicker